Betrixaban, also known as PRT054021, MK-4448; PRT-021; PRT-054021; MLN-1021, is a potent, orally active and highly selective factor Xa inhibitor undergone human clinical trials for prevention of embolism after knee surgery, and prevention of stroke following atrial fibrillation. Betrixaban is currently being studied in a human clinical trial for extended duration thromboprophylaxis to prevent venous thromboembolism in acute medically ill patients.
Synonyms:
N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide;
Bevyxxa®;
Betrixaban (USAN);
Factor Xa Related Products:
Apixaban; Rivaroxaban; Fondaparinux sodium; Betrixaban; Edoxaban tosylate; Milvexian